陳志龍教授
陳志龍，二級教授、博士生導師、主任藥師。為第二軍醫大學藥學學士、醫學博士（藥學專業），曾先后在中科院上海有機化學研究所、澳大利亞Central Queensland University、英國The University of Liverpool進行3次博士后研究。曾任第二軍醫大學防護醫學教研室主任、學科帶頭人。現為東華大學生物與醫學工程學院生物醫藥研究組課題組長，PI，藥物化學與藥理學教授，博士生導師。發表論文350余篇。出版英文專著2部、中文專著3部。申請國家發明專利90余項。培養博士后、博士與碩士研究生120余名。
研究方向:
1. 人工智能（AI）和計算機輔助（CADD）新藥研發；
2. 光敏新藥研發及光動力療法的基礎與應用研究（如抗腫瘤、抗鮮紅斑痣、抗類風濕性關節炎、抗菌抗病毒作用等）；
3. 靶向藥物研究（如抗腫瘤靶向新藥研究；降壓新藥研究；葉酸、多肽、單克隆抗體等靶向分子導向的新藥研究）；
4. 多功能、多模態藥物納米靶向制劑研究；
5. 中藥與天然藥物研究；
6. 藥物代謝、藥理毒理學及臨床藥學研究;
7. 醫學成像試劑研究。
榮譽及獲獎情況：
1. 第二軍醫大學 “學習成才十佳先進個人”；
2. 上海市“浦江人才”；
3. 南京市“創新創業人才”；
4. 上海市“優秀學術技術帶頭人”；
5. 嘉興市“科技領軍人才”;
6. 主持項目“光敏新藥與試劑的研制及光動力療法的基礎與應用研究”獲上海市藥學科技二等獎（2012年）;
7. 主持項目“光敏新藥與試劑的研制及光動力療法的基礎與應用研究”獲中國藥學科技三等獎（2013年）;
8. 參與項目（第二負責人）“光動力治療皮膚病關鍵技術創新及推廣應用”獲中華醫學科技三等獎（2017年）;
9. 主持，平湖市創新創業大賽一等獎----光敏新藥與試劑及降壓新藥研究開發（2018年）。
近年來承擔的主要科研項目：
承擔各類項目90余項，其中主持50余項。如主持各類人才基金5項、國家自然科學基金7項、軍隊醫藥衛生重大課題1項、上海市科委與教委重點項目7項、國際合作項目8項等。參與國家與國際重要課題6項，如國家新藥創制重大專項、國家自然科學基金重點項目等；指導團隊成員獲國家自然基金5項、國家與上海市博士后基金11項、上海市科委重點項目8項等。部分課題如下：
1. 國家自然科學基金（編號：21372042；30973611；30271534；30070862；29872055；21977016；22361132541等）。
2. 上海市優秀學術技術帶頭人人才計劃基金（編號：15XD1523400）。
3. 上海市浦江人才計劃基金（編號：06PJ14001）。
4. 上海市科委重大重點基金（編號：064319020; 10DZ0502300; 13431900700；14140903500；14431906200；15411960400；15431904100；17431902600；21430730100等）。
5. 科技部與上海市國際科技合作基金（編號：6-11、11BA1400700、13430722300、17430711900、17430741800、18430713000、20490740400、21430730100; 9-33等）。
6. 軍隊醫藥衛生重大項目（編號01L054）。
7. 上海市教委重點項目基金（編號：10ZZ45）。
8. 教育部科技研究重點項目（編號：108146）。
近年來發表的代表性論著、專利：
論文：
1. Tao Xu, Igor Vladimirovich Reshetov, Evgeniy Altarovna Kogan, Zhi-Long Chen*, et al. Quaternary ammonium cations conjugated 5,15-diaryltetranaphtho [2,3] porphyrins as photosensitizers for photodynamic therapy.European Journal of Medicinal Chemistry, 2024, 267, 116228.(SCI, Q1, TOP期刊)
2. Tao Xu, Le Mi, Zhi-Long Chen*, et al. Design, synthesis, and evaluation of 5,15- diaryltetranaphtho [2,3] porphyrins as photosensitizers in real-time photodynamic therapy and photodiagnosis. European Journal of Medicinal Chemistry, 2024, 264, 115980. (SCI, Q1, TOP期刊)
3. Ning Cao, Zhi-Long Chen*, et al. Synthesis and photodynamic activity of novel thieno[3,2–b]thiophene fused BODIPYs with good bio-solubility and anti-aggregation effect. Bioorganic Chemistry, 2024, 143, 107097. (SCI, Q1, TOP期刊).
4. Ning Cao, Zhi-Long Chen*, et al. Synthesis and evaluation of novelmeso-substitutedphenyldithieno[3,2-b]thiophene-fused BODIPY derivatives as efficient photosensitizers for photodynamic therapy. European Journal of Medicinal Chemistry, 2024, 264,116012. (SCI, Q1，TOP期刊)
5. Tabbisa Namulinda, Justus Kwetegyeka, Ivan Gumula, Yomen Atassi, Sami Karam, Zhi-Long Chen*, et al. pH-responsive Photinia glabra–zinc oxide–protoporphyrin IX nanoconjugates with enhanced cellular uptake for photodynamic therapy towards cancer cells. Nanomedicine, 2023, 19(2): 127-143. (SCI, Q1)
6. Tabbisa Namulinda, Zhi-Long Chen*, et al. Antibacterial and anticancer activities of green synthesized silver nanoparticles using Photinia glabra fruit extract. Nanomedicine, 2023, 18, (14): 987-1002. (SCI, Q1)
7. Jianbo Wu, Zhilong Chen, et al. The use of multidimensional nomial logistic model and structural equation model in the validation of the 14-item health-literacy scale in Chinese patients living with type 2 diabetes. Risk Management and Healthcare Policy, 2023, 16，1567-1579.（SCI, Q2）
8. Jianbo Wu, Zhilong Chen*, et al. Self-efficacy as moderator and mediator between medication beliefs and adherence in elderly patients with type 2 diabetes. Patient Preference and Adherence, 2023, 17, 217-226. (SCI, Q3)
9. Man?Yi Li, Zhi?Long Chen*, et al. The bromoporphyrins as promising anti-tumor photosensitizers in vitro. Photochemical & Photobiological Sciences, 2023, 22, 427-439. (SCI, Q2)
10. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new fluorinated pyropheophorbide-a derivatives for photodynamic therapy. Dyes and Pigments, 2022, 197, 109932.(SCI, Q1,TOP期刊)
11. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new pyropheophorbide-a derivatives for CAIX-targeted photodynamic therapy. Dyes and Pigments, 2022, 203,110328.(SCI, Q1, TOP期刊).
12. Man Yi Li, Zhi Long Chen*, et al, The biological activities of 5,15-diaryl-10,20-dihalogeno porphyrins for photodynamic therapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2335-2346. (SCI, Q2)
13. Refilwe Matshitse, Zhi-Long Chen, Tebello Nyokong, et al. Photodynamic therapy characteristics of phthalocyanines in the presence of boron doped detonation nanodiamonds: Effect of symmetry and charge. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102705. （SCI, Q3 ）
14. Faiza Sajjad, Zhi-Long Chen*, et al. Incorporation of green emission polymer dots into pyropheophorbide-α enhance the PDT effect andbiocompatibility. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102562.（SCI, Q3）
15. Man-Yi Li, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of novel fluorinated hematoporphyrin ether derivatives for photodynamic therapy. Bioorganic Chemistry, 2021, 107, 104528.(SCI, Q1,TOP期刊)
16. Faiza Sajjad, Zhi-Long Chen*, et al. Synthesis and invitro PDT evaluation of red emission polymer dots (R-CPDs) and pyropheophorbide-α conjugates. Scientific Reports. 2021, 11, 10013. (SCI, Q2)
17. Zhuo Wu, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of novel fluoro-substituted benzimidazole derivatives with anti-hypertension activities. Bioorganic Chemistry, 2020, 101, 104042.(SCI, Q1,TOP期刊)
18. Ying-Hua Gao, Zhi-Long Chen*. Synthesis and pharmacological evaluation of chlorin derivatives for photodynamic therapy of cholangiocarcinoma. European Journal of Medicinal Chemistry, 2020,189, 112049.(SCI, Q1,TOP期刊)
20. Ying-Hua Gao, Vanda Lovrekovi?, Zhi-Long Chen*, et al. The photodynamic activities of dimethyl 131-[2-(guanidinyl)ethylamino] chlorin e6 photosensitizers in A549 tumor. European Journal of Medicinal Chemistry, 2019, 177, 144-152. (SCI, Q1,TOP期刊)
21. Zhuo Wu, Yi-Jia Yan, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of AT1 receptor blockers derived from 6-substituted aminocarbonyl benzimidazoles. European Journal of Medicinal Chemistry, 2019,181,111553. (SCI, Q1,TOP期刊)
22. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al.Comparison between porphin, chlorin and bacteriochlorin derivatives for photodynamic therapy: Synthesis, photophysical properties, and biological activity. European Journal of Medicinal Chemistry, 2018, 160, 146-156. (SCI, Q1,TOP期刊)
23. Ping-Yong Liao, Zhi-Long Chen*, et al. Synthesis of 2-morpholinetetraphenylporphyrins and their photodynamic activities. Bioorganic Chemistry, 2017, 71: 299 - 304.(SCI, Q1,TOP期刊)
24. Li Wang, Wei Zhu, Zhi-Long Chen*, et al. Preparation of a chlorophyll derivative and investigation of its photodynamic activities against cholangiocarcinoma. Biomedicine & Pharmacotherapy. 2017, 92: 285-292. (SCI, Q1,TOP期刊)
著作：
1. Akmaral Kussayeva, Zhilong Chen, Davor Margeti?*，Synthesis of Pheophorbide a and Chlorin e6Photosentisizers, In：Photosensitizers and their Applications. Page 129-154. Editors: Davor Margetic and Renjith Thomas. Published by Nova Science Publishers, Inc. New York. July 27, 2022. ISBN: 978-1-68507-880-5.
2. Yi-Jia Yan, Danye Chen, Davor Margeti?*, Zhi-Long Chen*. Photosensitizers and their Applications in China. In: Photosensitizers and their Applications. Page 155-192. Editors: Davor Margetic and Renjith Thomas. Published by Nova Science Publishers, Inc. New York, July 27, 2022. ISBN: 978-1-68507-880-5.
3. Ronald N. Warrener, Davor Margetic, David A. Mann, Zhi-Long Chen, and Douglas N. Butler. Novel geometry polynorbornane scaffolds for chromophore linkage and spacing. Artificial Photosynthesis: From Basic to Industrial Application. Page 147-166. November 2005. Edited by Anthony F. Collings and Christa Critchley. Wiley-Verlag GmbH & Co. KgaA, Weinheim. ISBN: 3-527-31090-8.
4. 張黎明，陳志龍主編。《常見海洋生物傷防治指南》，第二軍醫大學出版社，2002年。
5. 姜成華，陳志龍主譯。《防化醫學手冊》，第二軍醫大學出版社，2001年。
6. 蔡建明，張建敏，陳志龍主編。《“三防”救治手冊》，2001年10月。
專利：
申請國家發明專利90余項。
主要學術兼職：
為中國光學會激光醫學分會常務理事；上海藥學會理事；上海生化藥物專業委員會副主任委員；上海藥物化學專業委員會委員；上海藥學會產學研創新工作委員會委員；上海市藥學會醫院藥學專委會委員；上海藥理學會治療藥物監測研究專委會委員；上海市抗癌協會腫瘤藥學專委會委員；上海市醫院協會臨床藥事管理專委會委員；上海市醫學會第六屆醫療事故鑒定專家庫成員；上海市醫學會第四屆預防接種異常反應鑒定專家庫成員。
為國家科學技術獎勵評審專家；科技部重大重點專項評審專家；國家自然科學基金評審專家；教育部計劃項目與博士點基金評審專家；上海市科委項目評審專家。
國際交流與合作：
與英國帝國理工學院（Imperial College of London, UK）利物浦大學（The University of Liverpool, UK）；愛爾蘭都柏林大學(University College Dublin, Ireland)；愛爾蘭皇家外科學院(Royal College of Surgeons in Ireland, Ireland)；美國新澤西立大學(Rutgers，The State University of New Jersey，US) ；澳大利亞中昆士蘭大學（Central Queensland University, Australia）；克羅地亞魯德爾博斯科維奇研究所(Rudjer Bo?kovi? Institute, Croatia) 、俄羅斯科學院（Institute of Russian Academy of Sciences, Russia）、俄羅斯莫斯科國立第一醫科大學(The First Moscow State Medical University named after I. M. Sechenov, Russia),、南非羅德斯大學(Rhodes University, South Africa)、緬甸仰光大學(University of Yangon, Myanmar)等多所大學與研究所有合作關系。
其它：
1. 研究團隊: 團隊成員30余名，含博士助手2名、化學與生物醫學博士后2名、博士碩士研究生二十余名、留學生6名。
2. 博士后招聘：招收藥學、化學、生物學、醫學、材料學等專業博士后。
3. 博士、碩士研究生招生：在化學、生物化學與分子生物學、生物與醫藥、生物醫學工程、材料學等專業的博士、碩士點，招收藥學、化學、生物學、醫學、材料學等專業背景研究生。
電話：021-67792654；E-mail：zhlchen@dhu.edu.cn; zlchen1967@qq.com
Prof. Zhi-Long Chen
Curriculum Vitae：
Zhi-Long Chen got his B.Sc. and Ph.D. of Medicinal Chemistry from Second Military Medical University in 1996. He once worked as postdoctoral fellow in Shanghai Institute of Organic Chemistry, Chinese Academy of Science (China); in Central Queensland University (Australia) and the University of Liverpool (England). Prof. Chen has published more than 350 papers and 5 academic books, applied more than 90 patents. His projects were supported by more than 90 grants from Chinese Government and Shanghai Governments. More than 20 products were prepared and used in factories.
Research interests:
1. The discovery of new drug based on artificial intelligence (AI) and computer-aided drug design (CADD).
2. The discovery and development of new photosensitizer drugs in photodynamic therapy, and photo-diagnosis to tumor, senile macular degeneration, actinic keratosis, port-wine stains, rheumatoid arthritis.
3. The discovery and development of new targeted drugs, including new anti-tumor drugs，new antihypertensive drugs and new molecular targeted drugs (folic acid, peptides, monoclonal antibodies, etc.).
4. The discovery of targeted nano drug delivery system with multi-function and multimodal effects.
5. The discovery of new drugs from natural products.
6. Studies on the pharmacology, toxicology, pharmacokinetics and mechanism of new drugs.
7. The discovery of new medical imaging agents.
Awards:
1. “Shanghai Pujiang Talents” in 2008 from Shanghai Science and Technology Bureau.
2. “Shanghai Outstanding Science and Technology Group Leader” in 2014 from Shanghai Science and Technology Bureau.
3. Zhi-Long Chen, Wen-Hui Chen, Yi-Jia Yan, etc. “Studies on the discovery of new photodynamic drugs and reagents, on the fundamental research and application of photodynamic therapy” got the awards from Shanghai Pharmacy Association in 2012.
4. Zhi-Long Chen, Wen-Hui Chen, Yi-Jia Yan, etc. “Studies on the discovery of new photodynamic drugs and reagents, on the fundamental research and application of photodynamic therapy” got the awards from Chinese Pharmacy Association in 2013.
5. Xiu-Li Wang, Zhi-Long Chen, Heng Gu, etc. “The key technic innovations and their application of photodynamic therapy in skin diseases” got the award from Chinese Medicine Association in 2017.
6. The first prize of “Innovation and Entrepreneurship Competition of Pinghu city” in 2018.
Main scientific research projects:
More than 90 projects were supported by Chinese central government and Shanghai city government and other city governments. Such as hosting 5 talent funds, 7 national natural science funds, 1 major military medical and health project, 7 key projects of the Shanghai Municipal Science and Education Commission, and 8 international cooperation projects. Some of the projects as follows:
1. Grants from National Natural Science Foundation of China (No. 21372042; 30973611; 30271534 ; 30070862; 29872055; 21977016; 22361132541,et al).
2. Grant from “Shanghai Outstanding Science and Technology Group Leader” programme，（No.15XD1523400）.
3. Grant from “Shanghai Pujiang Talent” programme（No. 06PJ14001）.
4. The key grants from Shanghai government (No. 064319020; 10DZ0502300; 13431900700; 14140903500; 14431906200; 15411960400; 15431904100; 17431902600; 21430730100, et al)
5. International collaboration grant from Ministry of Science and Technology of China, and Shanghai government(No. 6-11; 11BA1400700; 13430722300; 17430711900; 17430741800; 18430713000; 20490740400; 21430730100; 9-33, et al).
6. Major Military Medical and Health Project (No. 01L054).
7. Shanghai Education Commission Key Project Fund (No.: 10ZZ45).
8. Key Project of Science and Technology Research from the Ministry of Education of China (No. 108146).
Publications:
Papers:
1. Tao Xu, Igor Vladimirovich Reshetov, Evgeniy Altarovna Kogan, Zhi-Long Chen*, et al. Quaternary ammonium cations conjugated 5,15-diaryltetranaphtho [2,3] porphyrins as photosensitizers for photodynamic therapy. European Journal of Medicinal Chemistry, 2024, 267, 116228.(SCI, Q1, TOP Journal)
2. Tao Xu, Le Mi, Zhi-Long Chen*, et al. Design, synthesis, and evaluation of 5,15- diaryltetranaphtho [2,3] porphyrins as photosensitizers in real-time photodynamic therapy and photodiagnosis. European Journal of Medicinal Chemistry, 2024, 264, 115980. (SCI, Q1, TOP Journal)
3. Ning Cao, Zhi-Long Chen*, et al. Synthesis and photodynamic activity of novel thieno[3,2–b]thiophene fused BODIPYs with good bio-solubility and anti-aggregation effect. Bioorganic Chemistry, 2024, 143, 107097. (SCI, Q1, TOP Journal).
4. Ning Cao, Zhi-Long Chen*, et al. Synthesis and evaluation of novelmeso-substitutedphenyldithieno[3,2-b]thiophene-fused BODIPY derivatives as efficient photosensitizers for photodynamic therapy. European Journal of Medicinal Chemistry, 2024, 264,116012. (SCI, IF: 6.7, Q1，TOP Journal)
5. Tabbisa Namulinda, Justus Kwetegyeka, Ivan Gumula, Yomen Atassi, Sami Karam, Zhi-Long Chen*, et al. pH-responsive Photinia glabra–zinc oxide–protoporphyrin IX nanoconjugates with enhanced cellular uptake for photodynamic therapy towards cancer cells. Nanomedicine, 2023, 19(2): 127-143. (SCI, Q1)
6. Tabbisa Namulinda, Zhi-Long Chen*, et al. Antibacterial and anticancer activities of green synthesized silver nanoparticles using Photinia glabra fruit extract. Nanomedicine, 2023, 18, (14): 987-1002. (SCI,Q1)
7. Jianbo Wu, Zhilong Chen, Songbai Zheng, et al. The use of multidimensional nomial logistic model and structural equation model in the validation of the 14-item health-literacy scale in Chinese patients living with type 2 diabetes. Risk Management and Healthcare Policy, 2023, 16，1567-1579.（SCI,Q2）
8. Jianbo Wu, Zhilong Chen*, et al. Self-efficacy as moderator and mediator between medication beliefs and adherence in elderly patients with type 2 diabetes. Patient Preference and Adherence, 2023, 17, 217-226. (SCI, Q3)
9. Man?Yi Li, Zhi?Long Chen*, et al. The bromoporphyrins as promising anti-tumor photosensitizers in vitro. Photochemical & Photobiological Sciences, 2023, 22, 427-439. (SCI,Q2)
10. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new fluorinated pyropheophorbide-a derivatives for photodynamic therapy. Dyes and Pigments, 2022, 197, 109932.(SCI, Q1,TOP Journal)
11. Feng Wang, Zhi-Long Chen*, et al. Synthesis and evaluation of new pyropheophorbide-a derivatives for CAIX-targeted photodynamic therapy. Dyes and Pigments, 2022, 203,110328.(SCI, Q1, TOP Journal)
12. Man Yi Li, Zhi Long Chen*, et al, The biological activities of 5,15-diaryl-10,20-dihalogeno porphyrins for photodynamic therapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2335-2346. (SCI, Q2)
13. Refilwe Matshitse, Zhi-Long Chen, Tebello Nyokong, et al. Photodynamic therapy characteristics of phthalocyanines in the presence of boron doped detonation nanodiamonds: Effect of symmetry and charge. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102705. （SCI, Q3 ）
14. Faiza Sajjad, Zhi-Long Chen*, et al. Incorporation of green emission polymer dots into pyropheophorbide-α enhance the PDT effect andbiocompatibility. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102562.（SCI, Q3）
15. Man-Yi Li, Ying-Hua Gao, Zhi-Long Chen*, et al. Synthesis and evaluation of novel fluorinated hematoporphyrin ether derivatives for photodynamic therapy. Bioorganic Chemistry, 2021, 107, 104528.(SCI, Q1,TOP Journal)
16. Faiza Sajjad, Zhi-Long Chen*, et al. Synthesis and invitro PDT evaluation of red emission polymer dots (R-CPDs) and pyropheophorbide-α conjugates. Scientific Reports. 2021, 11, 10013. (SCI, Q2)
17. Zhuo Wu, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of novel fluoro-substituted benzimidazole derivatives with anti-hypertension activities. Bioorganic Chemistry, 2020, 101, 104042.(SCI, Q1,TOP Journal)
18. Ying-Hua Gao, Zhi-Long Chen*. Synthesis and pharmacological evaluation of chlorin derivatives for photodynamic therapy of cholangiocarcinoma. European Journal of Medicinal Chemistry, 2020,189, 112049.(SCI, Q1,TOP Journal)
19. Ying-Hua Gao, Zhi-Long Chen*, Synthesis and evaluation of novel chlorophyll a derivatives as potent photosensitizers for photodynamic therapy. European Journal of Medicinal Chemistry, 2020, 187, 111959.(SCI, Q1,TOP Journal)
20. Ying-Hua Gao, Vanda Lovrekovi?, Zhi-Long Chen*, et al. The photodynamic activities of dimethyl 131-[2-(guanidinyl)ethylamino] chlorin e6 photosensitizers in A549 tumor. European Journal of Medicinal Chemistry, 2019, 177, 144-152. (SCI, Q1,TOP Journal)
21. Zhuo Wu, Yi-Jia Yan, Zhi-Long Chen*, et al. Design, synthesis and biological evaluation of AT1 receptor blockers derived from 6-substituted aminocarbonyl benzimidazoles. European Journal of Medicinal Chemistry, 2019,181,111553. (SCI, Q1,TOP Journal)
22. Wei Zhu, Ying-Hua Gao, Zhi-Long Chen*, et al.Comparison between porphin, chlorin and bacteriochlorin derivatives for photodynamic therapy: Synthesis, photophysical properties, and biological activity. European Journal of Medicinal Chemistry, 2018, 160, 146-156. (SCI, Q1,TOP Journal)
23. Ping-Yong Liao, Zhi-Long Chen*, et al. Synthesis of 2-morpholinetetraphenylporphyrins and their photodynamic activities. Bioorganic Chemistry, 2017, 71: 299 - 304.(SCI, Q1,TOP期刊)
24. Li Wang, Wei Zhu, Zhi-Long Chen*, et al. Preparation of a chlorophyll derivative and investigation of its photodynamic activities against cholangiocarcinoma. Biomedicine & Pharmacotherapy. 2017, 92: 285-292. (SCI, Q1,TOP Journal)
Books:
1. Akmaral Kussayeva, Zhilong Chen, Davor Margeti?*，Synthesis of Pheophorbide a and Chlorin e6Photosentisizers, In：Photosensitizers and their Applications. Page 129-154. Editors: Davor Margetic and Renjith Thomas. Published by Nova Science Publishers, Inc. New York. 2022. July 27, 2022. ISBN: 978-1-68507-880-5.
2. Yi-Jia Yan, Danye Chen, Davor Margeti?*, Zhi-Long Chen*. Photosensitizers and their Applications in China. In: Photosensitizers and their Applications. Page 155-192. Editors: Davor Margetic and Renjith Thomas. Published by Nova Science Publishers, Inc. New York. 2022. Publication Date: July 27, 2022. ISBN: 978-1-68507-880-5.
3. Ronald N. Warrener, Davor Margetic, David A. Mann, Zhi-Long Chen, and Douglas N. Butler. Novel Geometry Polynorbornane Scaffolds for Chromophore Linkage and Spacing. Artificial Photosynthesis: From Basic to Industrial Application. Page 147-166. November 2005. Edited by Anthony F. Collings and Christa Critchley. Copyright @ 2005 Wiley-Verlag GmbH & Co. KgaA, Weinheim. ISBN: 3-527-31090-8.
4. Li-Ming Zhang, Zhi-Long Chen as chief editor. Guidelines for the Prevention and Treatment of Common Marine Biological Injuries, Published by Second Military Medical University Publishers, 2002.
5. Cheng-Hua Jiang, Zhi-Long Chen as main translator. Handbook of Preventive Medicine, Published by Second Military Medical University Publishers, 2001.
6. Jian-Ming Cai, Jian-Min Zhang, and Zhi-Long Chen. Three Prevention and Treatment Manual, 2001.
Patents:
More than 90 national invention patents have been applied.
Academic part-time jobs:
Prof. Zhi-Long Chen serves as committee member of Shanghai Association of Medicinal Chemistry, Shanghai Association of Pharmacy; committee member of Chinese Association of Laser Medicine; committee member of Shanghai Hospital Pharmacy Association; committee member of Therapeutic Drug Monitoring Research Committee of Shanghai Pharmacological Society; Committee of Shanghai Anti-Cancer Association and Clinical Pharmacy Management Committee of Shanghai Hospital Association; the member of Expert Pool for Shanghai Medical Association; the member of Medical Accident Appraisal and Identification of Abnormal Reactions to Vaccination of Shanghai Medical Association. Expert in the evaluation of major key projects of the Ministry of Science and Technology; Expert in the evaluation of the National Natural Science Foundation of China; Expert in the evaluation of the Ministry of Education's Program and Doctoral Program Fund; Expert in project evaluation from the Shanghai Municipal Commission of Science and Technology.
International Collaboration:
We have collaborations with scholars from UK (Imperial college of London; The University of Liverpool), Ireland (University College Dublin; Royal College of Surgeons in Ireland), US (Rutgers, The State University of New Jersey), Australia(Central Queensland University), Croatia(Rudjer Bo?kovi? Institute), Russia (Institute of Russian Academy of Sciences;The First Moscow State Medical University named after I. M. Sechenov), South Africa (Rhodes University),Myanmar(University of Yangon), et al which were supported by grants from Chinese central government and Shanghai city government.
Others:
Team:
We have a team more than 30 persons, including 2 assistants of PhD, 2 postdoctors, 8 Ph.D students and 14 Master students, 5 international students, 7 technicians.
Labs:
We have more than 300 m2 organic chemistry labs and biological labs in the University and 300 m2 outside the University.
Position Opportunity:
We accept students to our group to finish their Master degree and Ph. D. Postdoctoral research fellows and visiting scholars are also welcome.
Connecting Information:
E-mail: zlchen1967@qq.com; zhlchen@dhu.edu.cn;
Phone: 0086-21-67792654;
Address：Room 4110，Building 4, 2999 North Songjiang Renmin Road, Songjiang District, Shanghai, China. Postcode: 201620
